The effect of methylene blue on acute respiratory distress syndrome in Covid-19 disease

Phase 3

• Conditions: COVID 19 Disease.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200409047007N2
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

The patient has received remdesivir and corticosteroids and antibiotics and anticoagulants
At least one day and at most 5 days have passed since the patient's hospitalization.
O2 saturation for 10 minutes without oxygen is less than 89 and more than 75
Age between 18 to 75 year
Does not have a history of G6PD Deficiency
Absence of chronic renal failure with GFR <30
Absence of heart failure with EF<40%
Does not have COPD with CO2>45
The patient is not intubated
Does not have systolic Blood Pressure <90
Do not take SSRI, MAO Inhibitor drugs
Has not received plasma therapy, IVIG, hemoperfusion, Tocilizumab and plasmapheresis before administration of methylene blue
Does not be pregnant
The patient should be conscious

Exclusion Criteria

Patient dissatisfaction
History of allergy or gastrointestinal intolerance to methylene blue

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality. Timepoint: One month after entering the study. Method of measurement: Patient death.